Abstract

Background: Botulinum toxin A (BTX-A) has been approved for treatment of movement disorders and migraine. The widely assumed peripheral mechanism of action has been questioned by recent studies which demonstrated an axonal transport in the facial nerve and within central nerves. Findings in our laboratory suggested a central antinociceptive activity following axonal transport in the sciatic nerve. Methods: To characterize the axonal transport of BTX-A, the toxin’s enzymatic activity in the CNS was assessed using immunofluorescent detection of its cleaved substrate synaptosomal-associated protein 25(SNAP-25) following injections into the rat whisker pad and hind-paw, intramuscular injection into the gastrocnemius and intraneural injections into the sciatic nerve. Intraneural and intraganglionic colchicine was employed to block axonal transport. To investigate the significance ofaxonal transport for antinociceptive activity of BTX-A, we assessed the effect of peripheral and intraganglionic injections of low dose BTX-A in orofacial formalin-induced pain in rats. Results: Following whisker pad BTX-A injection, cleaved SNAP-25 was observed in the dorsal horn of the medulla. Cleaved SNAP-25 following subcutaneous, intramuscular and intraneural toxin injection in rat hind limbs was observed in corresponding segments of ipsilateral dorsal and ventral horn. Central SNAP-25 cleavage following BTX-A injection into the sciatic nerve was prevented by colchicine. In the ventral horn, BTX-A protease was localized within cholinergic neurons. Facial and intraganglionic injections of BTX-A prevented orofacial pain dependent on axonal transport in the trigeminal sensory nerve. Conclusions: Our results suggest that the axonal transport of BTX-A in different sensory and motor nerves commonly occurs after peripheral administration. Axonal transport in sensory neurons followed by central enzymatic activity is involved in botulinum toxin’s antinociceptive effects. The possible functional role of axonal transport in motor neurons remains to be examined. Acknowledgements: The antibody to cleaved SNAP-25 was a kind gift from Ornella Rossetto (University of Padua, Italy). The study was funded by the Croatian Ministry of Science, Education and Sport and theDeutscher Akademischer Austausch Dienst.

Highlights

  • Botulinum toxin A (BTX-A) has been approved for treatment of movement disorders and migraine

  • Following whisker pad BTX-A injection, cleaved synaptosomal-associated protein 25 (SNAP-25) was observed in the dorsal horn of the medulla

  • Central SNAP-25 cleavage following BTX-A injection into the sciatic nerve was prevented by colchicine

Read more

Summary

Background

Botulinum toxin A (BTX-A) has been approved for treatment of movement disorders and migraine. Findings in our laboratory suggested a central antinociceptive activity following axonal transport in the sciatic nerve

Methods
Results
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call